Clinical Trial Update: RELY-ABLE Long Term Multi-center Extension of Dabigatran Treatment in Patients With Atrial Fibrillation Who Completed RE-LY Trial [Phase 3]

View source ↗

Summary

This document reports results from RELY-ABLE, a long-term, multi-center extension study of dabigatran in patients with atrial fibrillation who completed the RE-…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atrial Fibrillation

Drugs mentioned

• Dabigatran (Dabigatran etexilate)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Atrial Fibrillation | Phase 3 | Status: COMPLETED | Results posted: 2014-04-08